KRAS and cancer: To test if this association occurred in larger populations of patients in publically available datasets, we tested the signature consisting of RUVBL1, HSPA9, and XPO1 genes against those of TCGA-derived cancer patient datasets which contained sufficient TP53 and KRAS mutations for statistically relevant analyses (see Materials and Methods).